Search

Your search keyword '"Fett W"' showing total 79 results

Search Constraints

Start Over You searched for: Author "Fett W" Remove constraint Author: "Fett W" Search Limiters Available in Library Collection Remove constraint Search Limiters: Available in Library Collection
79 results on '"Fett W"'

Search Results

1. Response-guided first-line therapy and treatment of relapse in aggressive lymphoma: 10-year follow-up of the PETAL trial

2. PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel, and CMF versus a standard-dosed epirubicin–cyclophosphamide followed by paclitaxel with or without darbepoetin alfa in primary breast cancer—outcome on prognosis

3. PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel and CMF versus a standard-dosed epirubicin/cyclophosphamide followed by paclitaxel ± darbepoetin alfa in primary breast cancer—results at the time of surgery

6. Correction:High-risk additional chromosomal abnormalities at low blast counts herald death by CML (Leukemia, (2020), 34, 8, (2074-2086), 10.1038/s41375-020-0826-9)

7. West German Study PlanB Trial: Adjuvant Four Cycles of Epirubicin and Cyclophosphamide Plus Docetaxel Versus Six Cycles of Docetaxel and Cyclophosphamide in HER2-Negative Early Breast Cancer

9. Abstract P1-11-01: Effectiveness, safety and quality of life (QoL) results from the German multicenter AVANTI study of 1st-line bevacizumab (BEV)-containing therapy in >2000 patients (pts) with advanced breast cancer (aBC)

11. Abstract P6-13-02: Efficacy of first-line bevacizumab (BEV)-containing therapy for poor-prognosis advanced breast cancer (aBC): Subgroup analyses of the German AVANTI observational study

12. Clonal Evolution and Blast Crisis Correlate with Enhanced Proteolytic Activity of Separase in BCR-ABL b3a2 Fusion Type CML under Imatinib Therapy

13. Abstract P4-13-26: Efficacy, safety, and treatment decision-making in the AVANTI German observational study of first-line bevacizumab (BEV)-containing therapy for locally advanced, recurrent, or metastatic breast cancer (aBC)

20. Local Recurrence Risk in 6377 Patients with Early Breast Cancer Receiving Neoadjuvant Anthracycline-Taxane plus /-Trastuzumab Containing Chemotherapy.

21. Pathological Complete Response after Neoadjuvant Chemotherapy plus Trastuzumab Treatment Predicts Survival and Detects a Patient Subgroup at High Need for Improvement of Anti-HER2 Therapy. Three Year Median Follow-Up Data of the TECHNO Trial

22. PD07-05: Local Recurrence Risk in 6377 Patients with Early Breast Cancer Receiving Neoadjuvant Anthracycline-Taxane +/− Trastuzumab Containing Chemotherapy.

23. Abstract P1-11-03: Pathological Complete Response after Neoadjuvant Chemotherapy + Trastuzumab Treatment Predicts Survival and Detects a Patient Subgroup at High Need for Improvement of Anti-HER2 Therapy. Three Year Median Follow-Up Data of the TECHNO Trial

29. Exopolysaccharides of the phytopathogen Pseudomonas syringae pv. glycinea

30. Dietary Re-education, Exercise Program, Performance and Body Indexes Associated with Risk Factors in Overweight/Obese Women

32. A multicentric observational trial of pegylated liposomal doxorubicin for metastatic breast cancer

33. Randomized Comparison of Interferon-α With Busulfan and Hydroxyurea in Chronic Myelogenous Leukemia

34. Influence of substituents on the solution conformation of the exopolysaccharide produced by Pseudomonas ‘gingeri’ strain Pf9

35. Structural investigation of the exopolysaccharide produced by Pseudomonas flavescens strain B62 . Degradation by a fungal cellulase and isolation of the oligosaccharide repeating unit

36. Identification of exopolysaccharides produced by fluorescent pseudomonads associated with commercial mushroom (Agaricus bisporus) production

37. Studies on the primary structure of short polysaccharides using SEC MALDI mass spectroscopy

38. The structure of the exopolysaccharide of Pseudomonas fluorescens strain H13

39. The structure of the acidic exopolysaccharide produced by Pseudomonas 'gingeri' strain Pf9

40. First-line bevacizumab-containing therapy for HER2-negative locally advanced/metastatic breast cancer: Real-world experience from >2000 patients treated in the multicentre AVANTI study.

41. A multicentric observational trial of pegylated liposomal doxorubicin for metastatic breast cancer.

42. Dietary Re-education, Exercise Program, Performance and Body Indexes Associated with Risk Factors in Overweight/Obese Women.

43. Production of rhamnolipids by Pseudomonas chlororaphis, a nonpathogenic bacterium.

44. Efficacy of ozone in killing Listeria monocytogenes on alfalfa seeds and sprouts and effects on sensory quality of sprouts.

45. Behavior of Listeria monocytogenes inoculated on cantaloupe surfaces and efficacy of washing treatments to reduce transfer from rind to fresh-cut pieces.

46. Analysis of native microflora and selection of strains antagonistic to human pathogens on fresh produce.

47. Naturally occurring biofilms on alfalfa and other types of sprouts.

48. Structural investigation of the exopolysaccharide produced by Pseudomonas flavescens strain B62--degradation by a fungal cellulase and isolation of the oligosaccharide repeating unit.

49. Mid-latency auditory evoked potentials in humans during anesthesia with S (+) ketamine--a double-blind, randomized comparison with racemic ketamine.

50. Alginate production by plant-pathogenic pseudomonads.

Catalog

Books, media, physical & digital resources